Reply letter to “response to article by Johnna Perdrizet et al.” by Gomez and colleagues

Johnna Perdrizet a, Carlos Felipe S. Santana b, Thais Senna b, Rodrigo Fernandes Alexandre d, Rodrigo Sini de Almeida e, Julia Spinardi f, and Matt Wasserman g

a Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA; b Health Economics and Outcomes Research, Pfizer Inc, Sao Paulo, Brazil; c Medical and Scientific Affairs, Pfizer Inc, Sao Paulo, Brazil

ABSTRACT

This communication seeks to address the questions and criticisms issued by Gomez and colleagues in their letter on our original study “Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.” Gomez and colleagues are concerned that the assumptions used in our model may have unintended negative impacts for Brazil decision-making and we intend to clarify any potential misinterpretation of our assessment.

ARTICLE HISTORY
Received 23 March 2021
Accepted 8 April 2021

1. Uncertainty in incidence rates is assessed and the best source for serotype distribution is used

Gomez and colleagues suggest an alternative data source for our base case invasive pneumococcal disease (IPD) incidence rates and question the appropriateness of SIREVA II for estimating serotype coverage. We agree that IPD incidence rates may present uncertainties, especially because, as we pointed in the limitations discussion, the data are from a passive laboratory surveillance system. Therefore, we rigorously tested IPD incidence rates in scenario analysis to assess the impact on results. As stated in our discussion “we tested the incidence data in scenario analysis using both Brazil and Chile IPD isolate case data [from SIREVA II]. Results showed that the use of PCV13 would remain cost saving compared with maintaining PCV10 in the Brazilian NIP, even when using other assumptions for IPD incidence rates.” The serotype coverage for PCVs were taken from a regional surveillance program (SIREVA II) implemented by the Pan American Health Organization (PAHO), which provides information on serotype distribution data for Streptococcus pneumoniae (Spn). It is important to note, that according to PAHO, the objective is to provide (1) a bank of biological material that allows the disease burden to be estimated, (2) direct national authorities in decision-making, (3) assist in determining the ideal PCV to be used in the region, and (4) facilitate the measurement of the impact of vaccine interventions. Therefore, we believe this is the best source to obtain the serotype prevalence for Brazil across all ages given the objective set by PAHO for this surveillance program.

2. Greater protection from more serotype coverage is estimated to reduce otitis media episodes

In Gomez and colleagues’ opinion, the reduction in acute otitis media (AOM) cases caused by switching to PCV13 may not occur because of PCV10’s impact on AOM caused by Nontypeable Haemophilus influenzae (NTHi). The protective effects of PCVs against AOM caused by NTHi is unknown, and additional evidence for both vaccines is necessary to quantify impact on AOM beyond Spn. However, specifically for PCV10, the Clinical Otitis Media and Pneumonia Study (COMPAS) conducted in Latin America did not find a significant effect on NTHi-clinically confirmed AOM. Our model predicts that broader serotype coverage afforded by PCV13 compared with PCV10 translates into further reductions of Spn AOM because of the substantial amount of 19A, 6A, and 3 disease circulating in Brazil. This is akin to real-world observations, where reduction in AOM cases have been observed in other countries when switching from a lower-valent to a higher-valent PCV.

3. Structural uncertainty was tested and confirmed conclusion that PCV13 is the most cost-effective option in Brazil

The cost-effectiveness model used for this Brazil study uses the same assumptions as many other peer-reviewed studies, including country examples for Mexico, Colombia, Finland, Netherlands, Canada, Malaysia, Italy, and Australia. This scientific methodology used for pneumococcal disease serotype trends has been recognized and is a strength of this study because we were able to show with numerous predictions from multiple countries the possible range of outcomes when switching to PCV13. These trends serve as a proxy for what Brazil can expect for a PCV13 NIP infant program and ultimately capture variations in uptake, antimicrobial resistance, underlying serotype dynamics, indirect effect, and historical schedules observed in other countries. Under these various scenarios, using the US, UK, Canada, and Quebec serotype dynamics, the conclusion for PCV13 remained the same; it
was more cost-saving and effective compared with maintaining PCV10.

4. Countries should consider epidemiological factors when evaluating a vaccine switch

The World Health Organization (WHO) states that PCV13 offers additional benefit in settings where disease attributable to serotype 19A and 6C is significant and countries should consider epidemiological factors, including substantial changes in the prevalence of vaccine serotypes and in antimicrobial resistance patterns, to assess any transition between vaccines.\(^{11}\)

The SIREVA II report from last years in Brazil brings not only the prevalence changes, pointing to further increases in 19A disease, but also a considerable change in the antimicrobial resistance profile once more related to this serotype. Our methods include serotype prevalence and therefore which serotypes are causing disease cases and deaths, which Gomez and colleagues unfortunately disagree with when assessing the appropriateness of a vaccine for the population. The methods used in this study are especially necessary in the current policy context to inform decision makers on PCV use given the significant progressive increase in 19A, 6A, and 3 in Brazil.

Disclosure of potential conflicts of interest

This work was supported by Pfizer Inc. All authors are employees of Pfizer Inc and may hold stock or stock options. All authors approved the final version of this reply letter publication.

Funding

Pfizer Inc. funded this reply letter publication.

ORCID

Johna Perdrizet http://orcid.org/0000-0002-4260-7607
Rodrigo Fernandes Alexandre http://orcid.org/0000-0002-1010-276X
Matt Wasserman http://orcid.org/0000-0003-3300-2742

References

1. Pan American Health Organization. SIREVA II (Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas). PAHO/WHO | SIREVA II (Spanish only); Washington, D.C., United States of America; [accessed 2021 Mar 1]. https://www.paho.org/hq/index.php?option=com_content&view=article&id=5536:2011-sireva-ii&Itemid=3966&lang=en.
2. Pastor I, Sings H, Hilton B, Kohli M, Kruse M, Wasserman M. A systematic review of pneumococcal conjugate vaccine (PCV) impact on acute otitis media (OM) and nasopharyngeal carriage (NP) due to nontypeable haemophilus influenza (NTHi). 35th annual meeting of the European society for paediatric infectious diseases; 2017; Madrid, Spain.
3. Tregnaghi MW, Saez-Llorens X, López P, Abate H, Smith E, Poslenos A, Calvo A, Wong D, Cortes-Barbosa C, Ceballos A, et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHID-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med. 2014;11(6):e1001657–e1001657. doi:10.1371/journal.pmed.1001657.
4. Dagan R, van der Beek BA, Ben-Shimol S, Pilishvili T, Givon-Lavi N. Effectiveness of the seven- and thirteen valent pneumococcal conjugate vaccines against vaccine-serotype otitis media. Clin Infect Dis. 2021. doi:10.1093/cid/ciab066.
5. Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, Zollo A, Icardi G. Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to the 10-valent pneumococcal conjugate vaccine (PCV10) in Italy. Pathogens. 2020;9(2):76. doi:10.3390/pathogens9020076.
6. Perdrizet J, Lai YS, Williams S, Struwig VA, Wasserman M. Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia. Infect Dis Ther. 2021;10(1):507–20. doi:10.1007/s40121-021-00409-7.
7. Pugh S, Wasserman M, Moffatt M, Marques S, Reyes JM, Prieto VA, Reijnders D, Rozenbaum MH, Laine J, Ahman H, et al. Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and The Netherlands: a cost-effectiveness analysis. Infect Dis Ther. 2020;9(2):305–24. doi:10.1007/s40121-020-00287-5.
8. Shafie AA, Ahmad N, Naidoo J, Foo CY, Wong C, Pugh S, Tan KK. Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Hum Vaccin Immunother. 2020;16(7):1719–27. doi:10.1080/21645515.2019.1701911.
9. Wasserman M, Palacios MG, Grajales AG, Baez FB, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560–69. doi:10.1080/21645515.2018.1516491.
10. Wilson M, Wasserman M, Jadavi T, Postma M, Breton M-C, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R, et al. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018;7(3):353–71. doi:10.1007/s40121-018-0206-1.
11. World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper. Wkly Epidemiol Rec. 2019;94(8):85–104.